Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa

Yuan, Hao; Zhang, Zhengyu; Hu, Lian-Dong

doi:10.1007/s13346-022-01188-5

Cited by 4 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, a gastroretentive floating matrix tablet can be developed to increase the drug’s residence duration in the stomach and boost bioavailability, where gastric retention time combined with longer drug release significantly improves patient compliance ( Joseph et al, 2018 ). A floating matrix tablet is an attractive strategy to develop controlled-release formulations and provides an easy and effective way to attain a prolonged stomach residence period and sustained drug release ( Yuan et al, 2023 ). Furthermore, controlled-release stomach-retentive dosage forms increase the bioavailability of medications with a limited window of absorption by allowing prolonged and continuous drug input to the upper gastrointestinal tract.…”

Section: Introductionmentioning

confidence: 99%

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Patel

Shelke²,

Surti³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

The present research is focused on developing floating matrix tablets of mitiglinide to prolong its gastric residence time for better absorption. Gastroretentive tablets were prepared using a direct compression technique with hydroxypropyl methylcellulose K15M (HPMC K15M) and sodium alginate as matrix-forming polymers and sodium bicarbonate as the gas-forming agent. A 32 full factorial design was adopted to optimize the flotation and release profile of the drug. The concentration of HPMC K15M and sodium alginate were taken as the independent variables, and the floating lag time, time required for 50% drug release, and time required for 90% drug release were taken as dependent variables. The compatibility between drug and excipients was assessed by Fourier transform infrared (FTIR) spectroscopy. The prepared tablets were evaluated for different parameters such as hardness, friability, drug content, floating time, in vitro dissolution, and stability. Dissolution data were analyzed using various kinetic models to ascertain the mechanism of drug release. Finally, a radiographic study was conducted to estimate the retention time of the optimized floating matrix tablets of mitiglinide inside the body. The results revealed that all the physical properties of the developed formulations were within standard limits. The formulation M3, with the maximum amount of both independent variables, was considered to be the optimized formulation based on the desirability value. In addition, the optimized M3 formulation showed stability for over 6 months, as evidenced by insignificant changes in lag time, drug release pattern, and other physical properties. Furthermore, radiographic examination indicated that the tablets remained afloat in gastric fluid for up to 12 h in the rabbit’s stomach. In conclusion, the developed floating matrix tablet of mitiglinide could be regarded as a promising formulation that could release the drug in the stomach at a controlled rate and, hence, offer better management of type II diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Patel

Shelke²,

Surti³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Drug Delivery Systems

Azagury,

Kaeek,

Khoury

et al. 2023

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Drug delivery systems (DDSs) and their administration routes play a critical role in the efficacy and safety of drugs. There are several physiological routes for drug delivery, including oral administration, injectables, inhalation, transdermal, intranasal, and transdermal delivery. This article focuses on these administration routes, describes their advantages and disadvantages, and elaborates on triggered and targeted DDS. Additionally, this article also describes drug release mechanisms from DDSs. DDSs are classified based on their physicochemical properties and administration routes. Pulsatile/stimuli systems allow controlled drug release at a specific time or location in response to an external stimulus. In addition, the controlled DDS employs several drug release mechanisms, such as diffusion, swelling, and erosion, to achieve the desired therapeutic effect. Representative applications of DDSs include the treatment of cancer, diabetes, and cardiovascular diseases. The COVID‐19 vaccine is a significant achievement in DDS, showcasing its potential to address global health crises. It utilizes lipid nanoparticles to encapsulate and protect mRNA, enabling targeted delivery to host cells. The mRNA instructs cells to produce the spike protein of the SARS‐CoV‐2 virus, triggering an immune response for COVID‐19 protection. In conclusion, DDSs and their administration routes are vital for safe and effective drug development, with recent advances such as pulsatile/stimuli systems showing promise for targeted delivery. The COVID‐19 vaccine development demonstrates the potential of DDS in tackling global health issues.

show abstract

Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis

Sun,

Zou,

Chen

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Cuproptosis, caused by an intracellular overload of copper (Cu) ions and overexpression of ferredoxin 1 (FDX1), is identified for its regulatory role in the skin wound healing process. This study verifies the presence of cuproptosis in skin wound beds and reactive oxygen species‐induced cells model. To address the two pathways leading to cell cuproptosis, a nanodrug‐engineered exosomes is proposed. A Cu‐chelator (Clioquinol, CQ) polydopamine (PDA)‐modified stem cell exosome loaded with siRNA‐FDX1, named EXOsiFDX1‐PDA@CQ, is designed to efficiently inhibit the two cuproptosis pathways. The functionalized exosomes are loaded into an injectable hydrogel and applied to treat diabetic wounds in mice and acute skin wounds in pigs. The local and controlled release of EXOsiFDX1‐PDA@CQ ensures the retention of the therapeutic agent at wound beds, effectively promoting wound healing. The strategy of engineered exosomes with functional nanoparticles (NPs) proposed in this study offers an efficient and scalable new approach for regulating cuproptosis.

show abstract

Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa

Cited by 4 publications

References 27 publications

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

Drug Delivery Systems

Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis

Contact Info

Product

Resources

About